Shanghai Hengrui Pharmaceutical Company
Shanghai Hengrui Pharmaceutical is working with Incyte on the development of treatments based on camrelizumab and thymosin. It is a humanized monoclonal antibody targeting PD-1 (Camrelizumab); 5-Da polypeptide hormone secreted by the thymus gland (thymosin). Chinese clinical trials assessing the combination treatment have been registered by Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) (ChiCTR2000029806) and Southeast University (NCT04268537).
Technology:
COVID
Industry:
Treatments
Headquarters:
China
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership